trial · primary record
Sacituzumab tirumotecan, Pembrolizumab
Ovarian Clear Cell Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 32 |
| Primary completion | 2030-01-31 |
| Primary endpoint | Objective Response Rate (ORR) assessed by the central review |
| Registry ID | NCT07913568 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:39.049Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07913568
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.